[{"indications": "Indications\u00a0see under Dose", "name": "RIFAMPICIN Combined preparations", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.9 Antituberculosis drugs", "RIFAMPICIN", "Combined preparations"], "cautions": "Cautions\u00a0see Monitoring in notes above; also liver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged\r\ntherapy, see also below); acute porphyria (section 9.8.2); important: effectiveness of hormonal contraceptives is reduced and alternative\r\nfamily planning advice should be offered (see also section 7.3.1); discolours soft\r\ncontact lenses; see also notes above; interactions: Appendix 1 (rifamycins)Note\u00a0If treatment interrupted re-introduce\r\nwith low dosage and increase gradually; discontinue permanently if serious side-effects developHepatic disorders\u00a0Patients or their\r\ncarers should be told how to recognise signs of liver disorder, and\r\nadvised to discontinue treatment and seek immediate medical attention\r\nif symptoms such as persistent nausea, vomiting, malaise or jaundice\r\ndevelop", "side-effects": "Side-effects\u00a0gastro-intestinal symptoms including anorexia,\r\nnausea, vomiting, diarrhoea (antibiotic-associated colitis reported);\r\nheadache, drowsiness; those occurring mainly on intermittent therapy\r\ninclude influenza-like symptoms (with chills, fever, dizziness, bone\r\npain), respiratory symptoms (including shortness of breath), collapse\r\nand shock, haemolytic anaemia, thrombocytopenic purpura, disseminated\r\nintravascular coagulation, and acute renal failure; alterations of\r\nliver function, jaundice; flushing, urticaria, and rashes; other side-effects\r\nreported include oedema, psychoses, adrenal insufficiency, muscular\r\nweakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis,\r\nStevens-Johnson syndrome, pemphigoid reactions, leucopenia, eosinophilia,\r\nmenstrual disturbances; urine, saliva, and other body secretions coloured\r\norange-red; thrombophlebitis reported if infusion used for prolonged\r\nperiod", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3918.htm", "doses": ["Brucellosis, legionnaires\u2019 disease, endocarditis and serious\r\nstaphylococcal infections, in combination with other drugs, by mouth or by intravenous infusion, 0.6\u20131.2\u00a0g daily (in 2\u20134 divided doses)", "Tuberculosis, in combination with other drugs, see notes above", "Leprosy, section 5.1.10", "Prophylaxis of meningococcal meningitis and Haemophilus\r\ninfluenzae (type b) infection, Table 2, section 5.1", "Name[Rifater\u00ae (Sanofi-Aventis) ] Tablets, pink, s/c, rifampicin 120\u00a0mg, isoniazid 50\u00a0mg, pyrazinamide 300\u00a0mg, net price 100-tab pack= \u00a321.95. \r\n    Label:\r\n    8, 14, 22, counselling, see lenses aboveDose\u00a0initial treatment of pulmonary tuberculosis, patients\r\nup to 40\u00a0kg 3 tablets daily preferably before breakfast, 40\u201349\u00a0kg\r\n4 tablets daily, 50\u201364\u00a0kg 5 tablets daily, 65\u00a0kg or more, 6 tablets\r\ndaily; not suitable for use in children"], "pregnancy": "Pregnancy\u00a0manufacturers advise very high doses teratogenic\r\nin animal studies in first trimester; risk of neonatal\r\nbleeding may be increased in third trimester; see also Pregnancy"}, {"indications": "Indications\u00a0see under Dose", "name": "RIFAMPICIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.9 Antituberculosis drugs", "RIFAMPICIN"], "cautions": "Cautions\u00a0see Monitoring in notes above; also liver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged\r\ntherapy, see also below); acute porphyria (section 9.8.2); important: effectiveness of hormonal contraceptives is reduced and alternative\r\nfamily planning advice should be offered (see also section 7.3.1); discolours soft\r\ncontact lenses; see also notes above; interactions: Appendix 1 (rifamycins)Note\u00a0If treatment interrupted re-introduce\r\nwith low dosage and increase gradually; discontinue permanently if serious side-effects developHepatic disorders\u00a0Patients or their\r\ncarers should be told how to recognise signs of liver disorder, and\r\nadvised to discontinue treatment and seek immediate medical attention\r\nif symptoms such as persistent nausea, vomiting, malaise or jaundice\r\ndevelop", "side-effects": "Side-effects\u00a0gastro-intestinal symptoms including anorexia,\r\nnausea, vomiting, diarrhoea (antibiotic-associated colitis reported);\r\nheadache, drowsiness; those occurring mainly on intermittent therapy\r\ninclude influenza-like symptoms (with chills, fever, dizziness, bone\r\npain), respiratory symptoms (including shortness of breath), collapse\r\nand shock, haemolytic anaemia, thrombocytopenic purpura, disseminated\r\nintravascular coagulation, and acute renal failure; alterations of\r\nliver function, jaundice; flushing, urticaria, and rashes; other side-effects\r\nreported include oedema, psychoses, adrenal insufficiency, muscular\r\nweakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis,\r\nStevens-Johnson syndrome, pemphigoid reactions, leucopenia, eosinophilia,\r\nmenstrual disturbances; urine, saliva, and other body secretions coloured\r\norange-red; thrombophlebitis reported if infusion used for prolonged\r\nperiod", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3914.htm", "doses": ["Brucellosis, legionnaires\u2019 disease, endocarditis and serious\r\nstaphylococcal infections, in combination with other drugs, by mouth or by intravenous infusion, 0.6\u20131.2\u00a0g daily (in 2\u20134 divided doses)", "Tuberculosis, in combination with other drugs, see notes above", "Leprosy, section 5.1.10", "Prophylaxis of meningococcal meningitis and Haemophilus\r\ninfluenzae (type b) infection, Table 2, section 5.1"], "pregnancy": "Pregnancy\u00a0manufacturers advise very high doses teratogenic\r\nin animal studies in first trimester; risk of neonatal\r\nbleeding may be increased in third trimester; see also Pregnancy"}, {"indications": "Indications\u00a0tuberculosis, \n(From 5.1.9 Antituberculosis drugs: British National Formulary)\n5.1.9 Antituberculosis drugs; prevention of tuberculosis (Table\r\n2, %s\n(From Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive(1): British National Formulary)\nPrevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive(1))", "name": "RIFAMPICIN WITH ISONIAZID", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.9 Antituberculosis drugs", "RIFAMPICIN WITH ISONIAZID"], "cautions": "Cautions\u00a0see Monitoring in notes above; also\r\nliver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged therapy (see also below); slow acetylator status (increased risk of side-effects); epilepsy; history of psychosis; alcohol dependence, malnutrition, diabetes mellitus, HIV\r\ninfection (risk of peripheral neuritis); acute porphyria (section 9.8.2); important: effectiveness of hormonal contraceptives is reduced and alternative\r\nfamily planning advice should be offered (see also section 7.3.1); discolours soft contact lenses; see also notes above; interactions: Appendix 1 (rifamycins, isoniazid)Note\u00a0Increased risk of side-effects\r\nif treatment interrupted and then re-introducedHepatic disorders\u00a0Patients or their\r\ncarers should be told how to recognise signs of liver disorder, and\r\nadvised to discontinue treatment and seek immediate medical attention\r\nif symptoms such as persistent nausea, vomiting, malaise, or jaundice\r\ndevelop", "side-effects": "Side-effects\u00a0gastro-intestinal symptoms including anorexia,\r\nnausea, vomiting, constipation, diarrhoea (antibiotic-associated colitis\r\nreported), alterations in liver function, jaundice, hepatitis (especially\r\nover age of 35 years); peripheral neuritis with high doses (pyridoxine\r\nprophylaxis, see notes above), optic neuritis, headache, drowsiness,\r\nconvulsions, psychotic episodes, vertigo; blood disorders (including\r\nleucopenia, haemolytic anaemia, aplastic anaemia, eosinophilia); dry\r\nmouth; flushing, urticaria, rash (including erythema multiforme),\r\npurpura; also reported pancreatitis, oedema, interstitial pneumonitis,\r\npsychoses, hyperreflexia, hyperglycaemia, adrenal insufficiency, gynaecomastia,\r\nmenstrual disturbances, difficulty with micturition, muscular weakness,\r\nmyopathy, systemic lupus erythematosus-like syndrome, pellagra, exfoliative\r\ndermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome,\r\nand pemphigoid reactions; urine, saliva, and other body secretions\r\ncoloured orange-red; hearing loss and tinnitus (in patients with end\r\nstage renal impairment); those occurring mainly on intermittent therapy\r\ninclude influenza-like symptoms (with chills, fever, dizziness, bone\r\npain), respiratory symptoms (including shortness of breath), collapse\r\nand shock,  haemolytic anaemia, thrombocytopenic purpura, disseminated\r\nintravascular coagulation, and acute renal failure; when used with\r\ntyramine or histamine rich foods, tachycardia, palpitation, hypotension,\r\nflushing, headache, dizziness, and sweating also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201688.htm", "doses": ["See preparations", "adult 50\u00a0kg and over, 2\r\ntablets daily, preferably before breakfast"], "pregnancy": "Pregnancy\u00a0see Pregnancy; isoniazid\r\nnot known to be harmful, but prophylactic pyridoxine recommended;\r\nmanufacturers advise very high doses of rifampicin teratogenic in animal studies in first trimester; risk of neonatal bleeding\r\nmay be increased by rifampicin in third trimester"}]